Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay).docVIP

BMC Clinical Pharmacology BioMedCentral Research article Open Access Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay) Tanmay S Panchabhai, Shaun F Noronha, Sanish Davis, Vishal M Shinde, Nilima A Kshirsagar and Nithya J Gogtay* Address: Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India Email: Tanmay S Panchabhai - tanmayp04@; Shaun F Noronha - smartshaun@; Sanish Davis - sanishdavis@; Vishal M Shinde - vishalmshinde@; Nilima A Kshirsagar - dcpkem@; Nithya J Gogtay* - njgogtay@ * Corresponding author Published: 24 October 2006 Received: 08 May 2006 Accepted: 24 October 2006 BMC Clinical Pharmacology 2006, 6:8 doi:10.1186/1472-6904-6-8 This article is available from: /1472-6904/6/8 ? 2006 Panchabhai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population). Methods: All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC. Results: It was seen that 10.36% of this populat